HSE has conducted a review of the approval of the active substance mepanipyrim and proposes to withdraw the approval.
HSE reviewed the approval of mepanipyrim in light of new scientific information which indicated that the active substance may no longer satisfy the criteria for approval.
The review considered the potential endocrine disrupting properties in humans and wild mammals for the EAS (oestrogen, androgen and steroidogenesis) modalities.
The review concluded that mepanipyrim met the criteria to be classified as having endocrine disrupting properties in humans for the EAS modalities.
HSE therefore proposes to withdraw approval of mepanipyrim in GB.
Details of this proposal will now be forwarded to the World Trade Organisation for consultation with trading partners.
Further information and developments relating to the approval of mepanipyrim will be recorded in the GB approval register on the HSE website.
Stakeholders should note that pesticides is in scope of the Sanitary and Phytosanitary (SPS) agreement currently being negotiated between the UK and the EU. Once negotiations on the SPS Agreement have concluded, HSE will communicate further on any implications the agreement has for the sector.
Contact us
If you have any questions relating to this ebulletin, please contact us.
|
